For years, technology vendors have pitched the benefits of virtual (decentralized) trials. Virtual trials are patient-centric and site-centric and can produce cost and efficiency benefits for sponsor companies. While adoption has been slow, the COVID-19 pandemic suddenly has companies scrambling for solutions that will protect patients and relieve the burden on sites. But are sponsors ready to embrace virtual trials? Join Clinical Leader Live for an informative discussion featuring:
- Brian Johnson, Director of Applied Innovation | Otsuka Pharmaceutical Companies (U.S.)
- Katherine Vandebelt, Global Head of Clinical Innovation | Oracle
Brian and Katherine have a combined 50 years of experience in pharma and will discuss how Otsuka has deployed virtual technologies, the challenges it faced, and how its trials are benefitting from the technology, as well as why more companies are not embracing virtual technologies and what more needs to be done to drive its adoption in the industry.